Inve India ▾

Fabtech Technologies share price & results

Fabtech Technologies Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Turnkey engineering solutions provider building GMP-compliant Process, Air (cleanroom/HVAC) and Water systems for pharma, biotech and healthcare facilities worldwide.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue49.2 ₹ crore+63.1% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin-0.5 %+29.1 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit1.1 ₹ crore—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.
Return on equity16.45 %−2.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-0.97 %+17.7 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)14.16 %−19.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

1 of 8 judged targets kept · 5 open · verdicts reflect calls analysed to Q1 FY27.

Fabtech Technologies Limited management guidance track record on Inve: 13 targets tracked across analysed earnings calls (1 achieved, 7 missed, 5 open).

TargetOriginal wordingSaidLatest callVerdict
FY26 RevenueBetween 380 to 400 crores
Call transcript, Q3 FY26 · 14 Feb 2026		Q3 FY26Q1 FY27:FY26 is complete. The final verdict stands.
Call transcript, Q1 FY27 · 28 Jul 2026		Achieved
Order Book Growth Rate7% to 9% growth per quarter in order conversions
Call transcript, Q2 FY26 · 10 Nov 2025		Q2 FY26Q1 FY27:Order book remained flat at 900 cr. New order inflow was 96.5 cr, but the total book did not grow, continuing to miss the 7-9% quarterly growth target.
Call transcript, Q1 FY27 · 28 Jul 2026		Missed
Order Book Conversion RateIncrease conversion rate to 20 to 25%
Call transcript, Q3 FY26 · 14 Feb 2026		Q3 FY26Q1 FY27:Management reported that 'Several large ticket opportunities have slipped due to the geopolitical conditions', suggesting a slowdown in conversions. This puts the 20-25% target at risk.
Call transcript, Q1 FY27 · 28 Jul 2026		At Risk

Source: Inve Guidance Tracker for Fabtech Technologies Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

7 of Fabtech Technologies Limited's 13 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 10 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹126.84 +3.79% · +₹4.63

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −38.8% 1Y

₹150₹200₹250Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 10 Nov 2025Q3 FY26 — 13 Feb 2026Q4 FY26 — 28 Apr 2026Q1 FY27 — 28 Jul 2026

1Y: ₹207.32 on 24 Oct 2025 → ₹126.84. High ₹255.41 (28 Oct 2025), low ₹119.96 (23 Oct 2026).

Previous close
₹122.21
Market cap
₹557 Cr
52-week range
₹119.96 – ₹255.41
One year
−44.49%
Price to earnings (TTM to Jun 2026)
11.44×
Return on equity (TTM to Jun 2026)
16.45%

Overview

Symbol
NSE:FABTECH
Exchange
NSE
Currency
INR

What Fabtech Technologies Limited does

Based on the company's own presentations, annual report and earnings calls.

Fabtech Technologies Limited, flagship of the Fabtech Group, delivers start-to-finish turnkey solutions for pharmaceutical, biotech and healthcare facilities, integrating design, engineering, in-house manufacturing, installation and validation. It operates across three integrated pillars — Precision Process Systems, Bio-Clean Air, and Pure Water — to build contamination-controlled, energy-efficient facility environments. The company runs an asset-light, integrated model with in-house manufacturing to minimise third-party dependency, and executes projects globally with operations anchored by UAE and Saudi Arabia and an expanding presence in Kenya and other African markets.

Segments

  • Process
  • Air
  • Water
Global presence
62 countries (operations anchored by UAE & Saudi Arabia)
Team size
180+ (incl. 94+ qualified engineers)
Secured projects
20 (as of Nov 3, 2025)
Core business verticals
3 — Process, Air (Cleanrooms/HVAC), Water
Group/subsidiary entities
13+ across Process, Air & Water verticals
Certification
ISO-certified operations
Headquarters Mumbai, Maharashtra, IndiaEmployees 180 (9M FY26) Company website

How the price took the results

close before → close after

Q1 FY27
+0.1%
28 Jul
Q4 FY26
+6.4%
28 Apr
Q3 FY26
−1.0%
14 Feb
Q2 FY26
+0.4%
10 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Fabtech Technologies Limited

Free account: one company. Everything above stays public.

Write why you follow Fabtech Technologies Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Fabtech Technologies Limited

Guides on how to read this kind of business and the numbers that matter.